372 related articles for article (PubMed ID: 26520368)
1. Cytogenetic evidence that DNA topoisomerase II is not involved in radiation induced chromsome-type aberrations.
Mosesso P; Pepe G; Ottavianelli A; Schinoppi A; Cinelli S
Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():14-8. PubMed ID: 26520368
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase II inhibitors fail to induce chromosome-type aberrations in etoposide-resistant cells: evidence for essential contribution of the cleavable complex formation to the induction of chromosome-type aberrations.
Suzuki H; Tarumoto Y; Ohsawa M
Mutagenesis; 1997 Jan; 12(1):29-33. PubMed ID: 9025094
[TBL] [Abstract][Full Text] [Related]
3. Efficient induction of chromosome-type aberrations by topoisomerase II inhibitors closely associated with stabilization of the cleavable complex in cultured fibroblastic cells.
Suzuki H; Ikeda T; Yamagishi T; Nakaike S; Nakane S; Ohsawa M
Mutat Res; 1995 May; 328(2):151-61. PubMed ID: 7739599
[TBL] [Abstract][Full Text] [Related]
4. Paraoxon and glyphosate induce DNA double-strand breaks but are not type II topoisomerase poisons.
Montero-Montoya R; Suárez-Larios K; Serrano-García L
Mutat Res Genet Toxicol Environ Mutagen; 2023; 890():503657. PubMed ID: 37567644
[TBL] [Abstract][Full Text] [Related]
5. Analyzing Mitotic Chromosome Structural Defects After Topoisomerase II Inhibition or Mutation.
Giménez-Abián JF; Lane AB; Clarke DJ
Methods Mol Biol; 2018; 1703():191-215. PubMed ID: 29177744
[TBL] [Abstract][Full Text] [Related]
6. Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage.
Adachi N; Suzuki H; Iiizumi S; Koyama H
J Biol Chem; 2003 Sep; 278(38):35897-902. PubMed ID: 12842886
[TBL] [Abstract][Full Text] [Related]
7. Post-treatment effects of DNA topoisomerase inhibitors on UVB- and X-ray-induced chromosomal aberration formations.
Ishii Y; Ikushima T
Mutat Res; 2002 Jul; 504(1-2):67-74. PubMed ID: 12106647
[TBL] [Abstract][Full Text] [Related]
8. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
9. Ku antigen is required to relieve G2 arrest caused by inhibition of DNA topoisomerase II activity by the bisdioxopiperazine ICRF-193.
Muñoz P; Baus F; Piette J
Oncogene; 2001 Apr; 20(16):1990-9. PubMed ID: 11360183
[TBL] [Abstract][Full Text] [Related]
10. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
11. Cytogenetic evaluation of the mechanism of cell death induced by the novel anthracenyl-amino acid topoisomerase II catalytic inhibitor NU/ICRF 500.
Cummings J; Sumner AT; Slavotinek A; Meikle I; Macpherson JS; Smyth JF
Mutat Res; 1995 Aug; 344(1-2):55-62. PubMed ID: 7565893
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events.
Ishida R; Sato M; Narita T; Utsumi KR; Nishimoto T; Morita T; Nagata H; Andoh T
J Cell Biol; 1994 Sep; 126(6):1341-51. PubMed ID: 8089169
[TBL] [Abstract][Full Text] [Related]
13. Concentration-response studies of the chromosome-damaging effects of topoisomerase II inhibitors determined in vitro using human TK6 cells.
Gollapudi P; Bhat VS; Eastmond DA
Mutat Res Genet Toxicol Environ Mutagen; 2019 May; 841():49-56. PubMed ID: 31138411
[TBL] [Abstract][Full Text] [Related]
14. Casein kinase II-dependent phosphorylation of DNA topoisomerase II suppresses the effect of a catalytic topo II inhibitor, ICRF-193, in fission yeast.
Nakazawa N; Arakawa O; Ebe M; Yanagida M
J Biol Chem; 2019 Mar; 294(10):3772-3782. PubMed ID: 30635402
[TBL] [Abstract][Full Text] [Related]
15. Dynamic behavior of DNA topoisomerase IIβ in response to DNA double-strand breaks.
Morotomi-Yano K; Saito S; Adachi N; Yano KI
Sci Rep; 2018 Jul; 8(1):10344. PubMed ID: 29985428
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.
Hasinoff BB; Kuschak TI; Creighton AM; Fattman CL; Allan WP; Thampatty P; Yalowich JC
Biochem Pharmacol; 1997 Jun; 53(12):1843-53. PubMed ID: 9256159
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase II inhibitor-induced apoptosis in thymocytes and lymphoma cells.
Kizaki H; Onishi Y
Adv Enzyme Regul; 1997; 37():403-23. PubMed ID: 9381984
[TBL] [Abstract][Full Text] [Related]
18. Catalytic inhibitors of topoisomerase II are DNA-damaging agents: induction of chromosomal damage by merbarone and ICRF-187.
Wang L; Eastmond DA
Environ Mol Mutagen; 2002; 39(4):348-56. PubMed ID: 12112387
[TBL] [Abstract][Full Text] [Related]
19. Tirapazamine: a hypoxia-activated topoisomerase II poison.
Peters KB; Brown JM
Cancer Res; 2002 Sep; 62(18):5248-53. PubMed ID: 12234992
[TBL] [Abstract][Full Text] [Related]
20. Cytological analysis of chromosome structural defects that result from topoisomerase II dysfunction.
Giménez-Abián JF; Clarke DJ
Methods Mol Biol; 2009; 582():189-207. PubMed ID: 19763951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
